

AD\_\_\_\_\_

GRANT NUMBER DAMD17-97-1-7087

TITLE: Magnetic Resonance-Guided Interstitial Laser  
Photocoagulation for the Treatment of Breast Cancer

PRINCIPAL INVESTIGATOR: Steven E. Harms, M.D.

CONTRACTING ORGANIZATION: University of Arkansas  
Little Rock, Arkansas 72205-7199

REPORT DATE: August 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

20001005 029

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 1999		3. REPORT TYPE AND DATES COVERED Annual (1 Aug 98 - 31 Jul 99)	
4. TITLE AND SUBTITLE  Magnetic Resonance-Guided Interstitial Laser Photocoagulation for the Treatment of Breast Cancer				5. FUNDING NUMBERS  DAMD17-97-1-7087	
6. AUTHOR(S)  Harms, Steven E., M.D.					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  University of Arkansas Little Rock, Arkansas 72205-7199				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) This study assesses magnetic resonance (MR)-guided interstitial laser photocoagulation (ILP) for the treatment of breast cancer. ILP has been successfully used for the treatment of a variety of solid tumors, and recent studies have indicated the capability of ILP, which employs low level heat (~50°C) for about 10 minutes, to kill breast cancer tissue. Because breast cancer cells are often interspersed with surrounding normal tissue, making boundaries difficult to define by most diagnostic imaging methods, MR imaging is used to define tumor margins and extent. Our research group has developed a high-contrast, high-resolution method for MR imaging of the breast, called RODEO (Rotating Delivery of Excitation Off-resonance), proven to have twice the sensitivity and specificity of mammography. Cellular death induced by ILP produces a phase change that can be visualized on MR images. This MRI hypointense zone can then be used to determine the adequacy of ILP treatment. The combination of RODEO imaging and a system for MRI-directed stereotaxic biopsy allows the accurate localization and placement of the laser fibers for ILP. This study tests the feasibility and outcome of MR-directed ILP in 30 patients with breast cancer who are scheduled for surgical removal of the lesion (mastectomy or lumpectomy). Our major findings to date are (1) RODEO MRI can accurately identify cancers for laser ablation; (2) Stereotaxic MRI needle positioning can be performed; (3) Fast RODEO MRI can accurately depict zones of ablation for interactive ILP; (4) ILP is an effective method for the minimally invasive ablation of breast cancer; (5) MRI-guided ILP is safe and is a potential alternative to surgical lumpectomy; and (6) MRI-guided ILP may have lower costs and provide better cosmesis than surgical lumpectomy.					
14. SUBJECT TERMS Breast Cancer  MRI, laser interstitial laser photocoagulation (ILP) stereotaxic, imaging				15. NUMBER OF PAGES 16	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT  Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE  Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT  Unclassified	20. LIMITATION OF ABSTRACT  Unlimited		

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

\_\_\_\_\_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

✓ \_\_\_\_\_ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

\_\_\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

\_\_\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
PI - Signature

7/27/99  
Date

## (4) TABLE OF CONTENTS

INTRODUCTION .....	1
SUBJECT .....	1
PURPOSE.....	1
SCOPE OF RESEARCH.....	1
BACKGROUND.....	1
Goals of Breast Cancer Therapy .....	1
ILP for Cancer Treatment.....	1
MR Imaging.....	2
Stereotaxis.....	2
MR control of ILP therapy for breast cancer .....	2
BODY .....	4
EXPERIMENTAL METHODS AND PROCEDURES .....	4
Stereotaxis.....	4
MR Imaging.....	4
ILP.....	5
MR/Pathology Correlations .....	5
Data Analysis .....	5
RESULTS AND DISCUSSION .....	6
Stereotaxis.....	6
MR Imaging.....	6
Interstitial laser photocoagulation.....	7
MR/Pathology correlation.....	7
SCHEDULED PRESENTATIONS .....	7
PUBLICATIONS .....	9
CONCLUSIONS.....	10
REFERENCES.....	9

## **(5) INTRODUCTION**

### **SUBJECT**

MR-directed ILP as an innovative alternative to breast conserving surgery.

### **PURPOSE**

To prove that combining minimally invasive treatment (ILP) with the diagnostic accuracy of MR imaging provides a treatment for breast cancer that is vastly superior cosmetically to breast conserving surgery, at a significantly lower cost.

### **SCOPE OF RESEARCH**

1. Demonstrate the potential of ILP for use as a minimally invasive therapy for breast cancer.
2. Demonstrate the capability of MR imaging to accurately localize breast cancer and stereotactically position needles for ILP.
3. Validate with rigorous MR/pathological correlation the capability of breast MR imaging to accurately determine the treatment zone resulting from ILP.

### **BACKGROUND**

#### **Goals of Breast Cancer Therapy**

The goals of current breast cancer treatment include early detection while the disease is confined to the breast and local control that results in minimal deformity. Because of the inability to accurately determine the extent of disease before therapy, more extensive treatment is often provided than is actually necessary to cure the disease. This tendency toward over-treatment results in greater morbidity for the patient and high costs for the health care system.

The highly accurate Magnetic Resonance Imaging (MRI) method for breast cancer used by our group was developed with the motivation that better depiction of lesion extent could dramatically improve the treatment of breast cancer. Recent studies demonstrate the capability of interstitial laser photocoagulation (ILP) for the minimally invasive treatment of solid tumors. In conjunction with Fischer Imaging (Denver, CO), we have developed a prototype stereotaxic biopsy table that is specifically designed for accurate MRI positioning. The goal of this research is to combine high resolution MRI definition of cancer extent, accurate stereotaxic MRI positioning, and ILP into an alternative method for breast conservation surgery. The use of this novel treatment approach would vastly improve cosmesis, reduce morbidity, and lower costs, thus eradicating some of the most detrimental effects of breast cancer therapy.

#### **ILP for Cancer Treatment**

ILP has recently been used as a minimally invasive treatment for certain solid tumors. It is based upon the local delivery of low-level heat (approximately 50°C) over a period of about 10 minutes. A percutaneous approach is used to place a laser fiber within the lesion using imaging guidance [1-10]. The extent of tissue destruction is a function of fiber position and the temperature gradients created with the interaction of the laser and the cellular components of the tissue. The necrotic tissue that is created by ILP subsequently heals by resorption, regeneration, and/or fibrosis [1-10].

In the United Kingdom, approximately 50 patients with breast cancer have been treated on an experimental protocol using ILP with ultrasound guidance [10]. The analysis of the surgical specimens following this treatment showed obliteration of the lesion, demonstrating the effectiveness of ILP for the

treatment of breast carcinoma. However, even though these early results show substantial promise for ILP as a potential treatment alternative for breast cancer, better imaging control than is presently available with sonographic or computed tomographic imaging is needed to determine disease extent and treatment effectiveness [10].

Unlike many solid tumors that have a well-defined interface with adjacent normal tissues, breast cancer infiltrates the surrounding tissue, making the margin difficult to appreciate on most imaging studies and even at surgery. The heterogeneity of breast tissue makes the theoretical prediction of laser heating effectiveness difficult. The surgical correlate of "free margins", obtained with the analysis of the pathology specimen, is needed to determine when ILP has sufficiently destroyed the tumor, leaving a margin of normal tissue. Recent studies have determined that MRI can identify the zones of regional heating resulting from ILP [11-14]. The cellular death induced by ILP produces a phase change that can be visualized on MR images. This MRI hypointense zone can be used to determine the adequacy of ILP treatment of breast cancer and directly define the extent of cell death. The most important role of MR in this setting is the ability to accurately define tumor and treatment margins.

## **MR Imaging**

A high contrast, high resolution MR imaging method called RODEO (ROtating Delivery of Excitation Off-resonance) was developed by our group specifically for breast cancer imaging. Since the introduction of this new imaging technique in 1991, over 1200 breast examinations have been performed by our research group. This breast MRI experience constitutes one of the world's largest series employing consistent MRI technology and represents the only large series of MRI/serially sectioned pathology correlation. Correlation with rigorous pathological analysis in over 400 serially sectioned mastectomy specimens has validated the accuracy of this method in demonstrating the extent of breast cancer. The sensitivity (94%) and specificity (66%) of RODEO breast MR were twice that of conventional breast imaging when the same cases were evaluated by readers who were blinded to the results of the other examination. In addition, the demonstration by MR imaging of additional, undetected disease foci in 38% of breasts closely approximates the reported prevalence of "subclinical" disease that is reported in rigorous pathological analyses. RODEO imaging can equally detect invasive carcinoma as well as ductal carcinoma *in situ* [24-29]. The remarkable ability of MR imaging to detect tumor margins and extent of disease indicates its potential for successful imaging control during ILP [15-29].

## **Stereotaxis**

Mammographically directed stereotaxic biopsy has become a recognized alternative to surgical biopsy for certain cases of breast cancer, with stereotaxic biopsy reliability now approaching that of surgical biopsy [30-32]. A variety of prototype stereotaxic devices have been built for MR-directed breast biopsy and needle localization [33-38]. These devices generally consist of components that provide breast immobilization, lesion localization, translation of MR imaging coordinates to spatial coordinates, and needle guidance. Since corrections for gradient nonlinearity are needed for accurate needle localization, all methods use some form of fiducial markers that reference the biopsy system to the MR coordinate system. This enables the accurate positioning of needles in three dimensions for subsequent treatment of the lesion using ILP.

## **MR control of ILP therapy for breast cancer**

The current surgical approach for breast conservation in the treatment of breast cancer, lumpectomy followed by analysis of the specimen and possible re-excision, requires several days of hospitalization for completion. Pathological analysis is used to determine the adequacy of the surgical resection. Often (40-70% of cases), the presence of positive margins associated with the lumpectomy specimen requires

additional surgery, either re-excision or mastectomy [39-43]. A Japanese study employing rigorous pathological analysis demonstrated a 95% positive margin rate in simulated lumpectomies [44]. In addition, incomplete tumor excisions and residual microscopic carcinoma may be associated with higher recurrence rates, as suggested by the tendency of larger tumors to recur more frequently [43].

MR-guided ILP, on the other hand, could be vastly more efficient and effective, involving only 2 hours of the patient's time for complete obliteration of the tumor. ILP offers a minimally invasive treatment for breast cancer while MRI accurately defines cancer extent and determines the zone of cellular death. In addition, stereotaxis MRI positioning provides the degree of accuracy needed for insertion of the laser and eliminates the need for breast compression. This unique combination of interactive treatment and diagnostic modalities could improve patient care through reduced morbidity, better cosmesis, and removal of the discomfort of breast compression, while, at the same time, lowering health care costs through less surgery and hospitalization time. For the patient with breast cancer, this means that local anesthesia and a needle puncture could replace the current regimen of surgery, hospitalization, general anesthesia, recovery, and breast deformity.

Our study tests the feasibility and outcome of MR-directed ILP in 30 patients with breast cancer who are scheduled for surgical removal of the lesion (mastectomy or lumpectomy). We expect our results will indicate that MR-directed ILP is a minimally invasive alternative to breast cancer surgery that can significantly reduce the costs of treatment by eliminating the need for surgery, hospitalization, and anesthesia, while eradicating the deformity resulting from breast surgery and changing the societal perception of breast cancer treatment.

## **(6) BODY**

### **EXPERIMENTAL METHODS AND PROCEDURES**

We currently have funding to conduct breast MR examinations in a series of patients who have suspicious mammographic or clinical findings. A series of 30 patients who are planning to undergo surgery for removal of the lesion will be selected from this existing study for participation in the proposed trial. Entrance criteria include:

1. Focal lesion on MRI with a maximum lesion diameter of 1.5 cm (may be associated with other lesions, but for the purposes of this pilot study, only one lesion will be treated with MR-guided ILP).
2. No previous radiation therapy to the breast.
3. No previous surgery on the lesion to be treated.
4. No contraindications to MR imaging or gadolinium contrast agent.

Patients will be paid \$300 for participation in this study.

### **Stereotaxis**

Patient positioning and breast stabilization are essential for obtaining accurate stereotaxis and, thus, successful implementation of MR-guided ILP.

A commercial prototype MR imaging stereotaxic localization and biopsy unit manufactured by Fischer Imaging (Denver, CO) will be utilized for this study (See Figure, Addendum B). The expertise of Fischer Imaging, the original manufacturer of stereotaxic mammography systems, has been used for the development of this unit, which exploits the unique advantages of MR imaging and eliminates some of the undesirable features of mammography-directed stereotaxis. Fischer has replaced the existing table (General Electric, Milwaukee, WI) with a table constructed from non-ferromagnetic composite material, which allows access to the entire breast from below. The Fischer device is designed for the highly accurate placement of needles and localization wires using a sophisticated c-arm. This allows fast, accurate placement of needles and localization wires at multiple locations. The c-arm approach is unique for MR imaging localization and allows flexibility in the selection of approaches so that the needle tract can be included in the operative field.

In conjunction with this prototype unit, thermal setting plastic will be used to achieve breast stabilization as an alternative to breast compression, which is employed by mammography and most other MRI stereotaxis systems. The thermal setting plastic is highly flexible when warmed and can adopt a shape that is individual for each breast. When the plastic cools to room temperature, it forms a rigid exoskeleton around the breast that facilitates consistent positioning for stereotaxis. This innovative approach to breast stabilization eliminates the need for painful breast compression, a frequently cited problem of mammography.

### **MR Imaging**

All studies will employ a high resolution, high contrast RODEO pulse sequence that has the capability of accurate tumor localization based upon validation by over 400 serially sectioned pathology specimens. MR compatible localization wires and biopsy needles are supplied by EZM (Westbury, NY).

After the patient has been positioned on the table and the breast has been stabilized with the thermal setting plastic, pre- and post-contrast 128-slice RODEO scans will be obtained for localization. Gadopentetate dimeglumine will be used as the contrast medium and will be administered as an intravenous bolus at 0.1 mmol/kg (8-16 ml). Fiducial markers will be used to correct for gradient nonlinearity of the MR imaging coordinates, providing 3D markers for localization and subsequent



positioning of the needle. While remaining in position on the stereotaxic table, the patient will be moved to the front of the magnet where the stereotaxic c-arm is located. The patient will then receive a local anesthetic, and, using the c-arm, a needle will be placed into the center of the lesion. A laser fiber will then be inserted into the needle to the center of the projected treatment zone.

## ILP

After the laser fiber has been successfully placed, the patient will be returned to the magnet center, and laser ablation will begin. The ILP therapy will closely follow the methods used by Bown et al [1-3, 10]. A Nd-YAG laser will be used at a power of 1-2 Watts, providing a temperature of about 50°C. The treatment will last approximately 10 minutes, but the hypointense zone that is seen on MRI will determine total treatment time.

During laser ablation, MR scans will be obtained at 2-minute intervals using rapid 32-slice acquisitions. During heating, a zone of hypointensity will appear on the MR images around the laser tip due to the phase change resulting from the cellular death. When this hypointense zone adequately covers the post-contrast tumor image as well as an adequate disease-free margin, the heating will be discontinued.

## MR/Pathology Correlations

At the conclusion of ILP therapy, the patient will again be moved from the magnet center to the stereotaxic c-arm at the front of the magnet. Using the c-arm, localization wires will be placed at the margins of the hypointense region. These will be used as boundary markers of the treatment zone for subsequent histopathology examination. At least two wires will be used to mark the maximum dimensions of the treatment zone. A repeat MR examination will be performed to confirm the wire position. The patient will then undergo surgery, either lumpectomy or mastectomy, for removal of the lesion. Pathology examination of the excised tissue will be used to determine the position of the localization wires relative to the zone of cellular death.

The proximity of the wire to the tumor and zone of cellular death will be measured in millimeters on the histology slide. The nature of the boundary zone will be analyzed to determine the significance of the MRI signal pattern. The extent of cellular destruction relative to the laser tip will be analyzed and compared to data we have obtained from animal models. Thorough pathological analysis of the specimen will be performed to evaluate potential skip areas, and the consistency, distribution, and effectiveness of ILP will be determined.

## Data Analysis

**ILP therapy:** The capability of ILP as a method for the minimally invasive treatment of breast cancer will be measured by rigorous pathological analysis of the surgical specimen. Either the lumpectomy or the mastectomy specimen will be serially sectioned with liberal histological sampling. The tissue will be analyzed for the location and extent of charring, cellular destruction, and hemorrhage relative to the position of the laser fiber and the margins of the hypointense MRI zone. In particular, we will evaluate the consistency of the laser effect and the potential for asymmetric or skipped areas. These data will be compared to previous results from animal model studies performed in our laboratory and to results reported in the literature. The data will be used to validate the ability of ILP to effectively destroy breast cancer cells *in vivo* and leave a disease-free margin.

**MRI localization for stereotaxis:** MR images will be interpreted prospectively by the PI, and stereotaxic positioning will be performed based upon this interpretation. At the end of the study, the ability of radiologists to interpret the MRI information for ILP treatment positioning will be evaluated retrospectively. To test the reliability of MRI for lesion identification and localization, three radiologists

who are blinded to the initial location selection will be asked to select a position for centering the laser. The variability and accuracy of selection of the three radiologists will then be determined retrospectively.

**MRI treatment control:** The MR images that are obtained during ILP will be interpreted prospectively by the PI to determine when an adequate hypointense zone is achieved. To test the capability of radiologists to consistently interpret these data, three radiologists will be asked to retrospectively define the hypointense zone on the final set of treatment images. The accuracy and variations among radiologists will be determined using the pathology gold standard. The histological and biochemical changes in the pathology specimen will be analyzed and correlated with the location of the MRI signal changes and the location of the laser fiber tip. The questions we hope to answer are:

Can MRI detect asymmetric heating or potential skip areas?

What is the histological appearance of the boundary zone?

Is MRI an adequate control method for ILP?

## **RESULTS AND DISCUSSION**

In the proposal, a total of 30 patients were to be treated over three years. Twenty-nine patients have been treated to date with 67 applications of MRI-guided interstitial laser photocoagulation. All procedures were well tolerated by the patients. In the first patient, IM Demerol was used in preparation for potential anxiety and/or pain. This patient felt that the procedure did not warrant narcotics. Subsequent patients were given oral Xanax 0.5 mg prior to the procedure in addition to local anesthesia.

Three patients had significant (second and third degree) skin burns up to 1 cm in diameter that were excised at surgery. One of these burns resulted when a fiber slipped back into the needle and heated the needle. This was corrected with a special locking hub that was devised and used on subsequent patients. The other smaller burns resulted when the fiber tip was inaccurately placed beyond lesions near the skin surface. No patients had infection or significant hematoma. . All of these patients have undergone surgical removal of the area. There were 12 mastectomies and 17 lumpectomies.

### **stereotaxis**

The MRI stereotaxic device from Fischer Imaging has been delayed due to the need for equipment modifications and the study was initiated with a device from MRI Devices, Inc. This device is now commercially available and being used in the ongoing NCI sponsored multicenter trial. This device has lower accuracy than the Fischer unit but was adequate for needle placement for a single fiber. During year 2, the Fischer device was delivered and tested. This system was limited in its ability to adequately stabilize the breast. For this reason, the Fischer unit was not employed for any of our study patients. We have developed our own system that fulfills most of our goals for stereotaxis including 1) accuracy, 2) speed, and 3) flexibility in pathway selection. With this system, we can easily deploy multiple needles and fibers.

The MRI-compatible needles from EZM have worked adequately. The major problem is that the artifact from the metal obscures a portion of the ablation zone. Once the fiber is in place, the needle can be slipped back to leave a bare fiber in the lesion. This manipulation eliminates the artifact problem but could potentially move the fiber tip from the desired position. Recently, EZM needles have not been available and they may not continue to manufacture. We have also used some new needles from Daum but they have a similar artifact problem. This problem can only be eliminated with a new laser introducer system that employs non-ferromagnetic materials.

### **MR Imaging**

The RODEO pulse sequence has accurately identified the cancers and margins in all cases [15-25].

Fast 1-minute RODEO images (32-64 slice 3D acquisitions) have accurately depicted the hypointense ablation zone in all cases. At the end of the treatment, a high resolution post-contrast RODEO is used to measure the ablation zone in three dimensions.

New imaging technology is being developed for faster image acquisition and higher contrast.

### **Interstitial laser photocoagulation**

The Nd-YAG laser has been replaced with a diode laser (Diomed, Cambridge, UK). The diode laser has a similar wavelength (805 nm) and can be split into four separate fibers for treating a larger area. After placement of the fiber, the fiber tip is pre-charred with 25 watts of power for 3 seconds. Subsequently, the power is reduced to 3 watts for a duration of about 10 minutes. This method has been widely employed by Bown et al [1-10]. The laser position and duration is interactively controlled by the fast RODEO images that are obtained during the ablation.

### **MR/Pathology correlation**

All of the patients have undergone surgery for removal of the cancers. The histology of the specimens by patient numbers were: invasive ductal carcinoma grade I-4, invasive ductal carcinoma grade II-6, invasive ductal carcinoma grade III-16, invasive lobular carcinoma-2, and papillary carcinoma with grade II DCIS-1. Twelve were surgically treated with mastectomy. The mastectomy specimens were sampled with serial pathologic sectioning. This method employs chilling of the breast tissue until firm and subsequent sectioning of the tissue at 5-mm increments. This method has been adopted by the International Breast MRI Consortium as a gold standard for accuracy measurement of breast MRI [15]. The remaining seventeen patients had lumpectomies with sectioning of the lumpectomy specimen at 5-mm increments. The size of the ablation zone is measured grossly and with the use of a UV lamp. Ample histologic sectioning of the area of treatment is used to measure the potential for ablation zone irregularities or skipped regions. The PCNA stain is used to demonstrate the lack of DNA replication as a signature of cellular death that cannot be seen on standard H&E stains. The PCNA stain can show the ablation zone within one hour after ILP. The size of the ablation zone for correlation with MRI is measured on a PCNA-stained section cut through the center of the ablation zone. In all cases, the ablation zone size has correlated within 1 mm with the MRI depicted area of hypointensity. No skip areas have been found within the ablation zone. The placement of wire markers for ablation zone marking has not been possible due to inaccuracies in the stereotaxic device

## **PRESENTATIONS**

### **1998**

*University of South Florida Medical Center*

*May 6-8, Key West, FL*

- "New Frontiers: MR Imaging of the Breast: Current Status and Future Potential"

*University of South Florida College of Medicine Breast Imaging Update July 12-19, 1998, Alaska*

- "Breast MRI: The Essentials"

*U.S. Public Health Services Office on Women's Health*

*September 8, 1998, Washington, DC*

- "International MRI Expert Working Group"; "Current and Potential Role in Local Staging: Implications for Treatment Options"

*Colorado Radiological Society, University of Colorado Health Services Center*

October 8-9, 1998, Denver, CO

- "Integration of Breast Magnetic Resonance Imaging with Breast Cancer Treatment"

Southwest Oncology Group

October 22-23, 1998, San Antonio, TX

- "Potential Use of Breast MRI in Clinical Trials"

The Wendy & Emery Reves International Breast Cancer Symposium, October 16-19, 1998, Dallas, TX

- "RODEO MRI Guided Laser Lumpectomy: The Potential for Treatment Without Disfigurement"

Vanderbilt University Medical Center, Department of Radiology and Radiological Sciences School of Medicine

November 2, 1998, Nashville, TN

- "New Frontiers in Breast MRI"

NSABP

November 18-19, 1998, Pittsburgh, PA

- "Overview of MRI Current Abilities and Future Needs"

Radiology Society of North America (RSNA)

Nov 29-December 4, 1998, Chicago, IL

- "Laser Lumpectomy with Interactive MR Imaging: Histopathological Correlation"

## 1999

The International Society for Optical Engineering (SPIE)

Jan 23-24, 1998, San Diego, CA

- "RODEO MRI Guided Laser Ablation of Breast Cancer"

The Sally Jobe Breast Centre – Breast Imaging & Intervention into the 21<sup>st</sup> Century

- "MRI, An Expanding Role"

Feb 2-12, 1999, Sanibel, FL

16<sup>th</sup> Annual Miami Breast Cancer Conference

Feb 25-27, 1999, Miami, FL

- "MRI in the Detection, Diagnosis and Staging of Breast Cancer"
- "Integration of MRI and Treatment Planning"

Southern Surgeons Club – Annual Meeting

May 3, 1999, Little Rock, AR

- "MRI and Breast"

Arkansas Public Health Association

May 6, 1999, Hot Springs, AR

- "RODEO MRI"

21<sup>st</sup> Family Practice Intensive Review Course

June 6, 1999, Little Rock, AR

- "MRI & Breast Imaging Update"

Rural Hospital Program Compressed Video Network

June 8, 1999, Little Rock, AR

- "MRI Breast Imaging Techniques"

Alumni Weekend

June 12, 1999, Little Rock, AR

- "Breast MRI Update"

National Surgical Adjuvant Breast & Bowel Project

June 21, 1999, Toronto, Canada

- "MRI Imaging of the Breast"

## **PUBLICATIONS**

1. Harms SE, Mumtaz H, Hyslop B, Klimberg S, Westbrook K, Korourian S: Magnetic Resonance Imaging Directed-Laser Lumpectomy. *Breast Diseases, A Year Book Quarterly*, St. Louis; Mosby. 1998.
2. Harms SE, Mumtaz H, Hyslop B, Klimberg VS, Westbrook K, Korourian S. RODEO-MRI guided laser ablation of breast cancer. SPIE 1999; 3590:484-489.

## **(7) CONCLUSIONS**

Preliminary results would indicate that:

1. RODEO MRI can accurately identify cancers for laser ablation.
2. Stereotaxic MRI needle positioning can be performed.
3. Fast RODEO MRI can accurately depict zones of ablation for interactive ILP.
4. ILP is an effective method for the minimally invasive ablation of breast cancer.
5. MRI-guided ILP is safe and is a potential alternative to surgical lumpectomy.
6. MRI-guided ILP may have lower costs and provide better cosmesis than surgical lumpectomy.

## (8) REFERENCES

1. Bown SG. Phototherapy of tumours. *World J Surg* 1983; 7:700-709.
2. Steger AC, Lees WR, Walmsley K, Bown SG. Interstitial laser hyperthermia: a new approach to local destruction of tumors. *Br Med J* 1989; 299:362-365.
3. Masters A, Bown SG. Interstitial laser hyperthermia in tumour therapy. *Ann Chir Gynecol* 1990; 79:244-251.
4. Storm FK, Sliberman AW, Ramming KR, et al. Clinical thermochemotherapy: a controlled trial in advanced cancer patients. *Cancer* 1984; 53:863-868.
5. Matthewson D, Coleridge-Smith P, O'Sullivan JP, Northfield TC, Bown SG. Biological effects of intrahepatic neodymium:yttrium-aluminum-garnet laser photocoagulation in rats. *Gastroenterology* 1987; 93:550-557.
6. Nolsoe CP, Torp-Pedersen S, Burcharth F, Horn T, Pedersen S, Christensen NH, Olldag ES, Andersen PH, Karstrup S, Lorentzen T, Holm HH. Interstitial hyperthermia of colorectal liver metastases with a US-guided Nd-YAG laser with a diffuser tip: a pilot clinical study. *Radiology* 1993; 187:333-337.
7. Amin Z, Donald JJ, Masters A, Kant R, Steger AC, Bown SG, Lees WR. Hepatic metastases: interstitial laser photocoagulation with real-time US monitoring and dynamic CT evaluation of treatment. *Radiology* 1993; 187:339-347.
8. Jacques SL, Rastegar S, Motamedi M, et al. Liver photocoagulation with diode laser (805 nm) vs Nd:YAG laser (1064 nm). *Proc SPIE* 1992; 1646:107-117.
9. Schatz SW, Bown SG, Wyman DR, Groves JT, Wilson BC. Low power interstitial Nd-YAG laser photocoagulation in normal rabbit brain. *Lasers in Medical Science* 1992; 7:433-439.
10. Harries SA, Masters A, Lees WR, Scurr J, Cook J, Cooke M, Smith M, Kissin M, Bown SG. *European J of Surgical Oncology* 1993; 19:217-217.65.
11. Jolez FA, Bleier AR, Jakab P, Ruenzel PW, Huttl K, Jako GJ. MR imaging of laser-tissue interactions. *Radiology* 1988; 168:249-253.
12. Anzai Y, Lufkin RB, Saxton RE, et al. Nd:YAG interstitial laser phototherapy guided by magnetic resonance imaging in an ex vivo model: dosimetry of laser-MR-tissue interaction. *Laryngoscope* 1991; 101:755-760.
13. Le Bihan D, Delannoy J, Levin RL. Temperature mapping with MR imaging of molecular diffusion: application to hyperthermia. *Radiology* 1989; 171:853-857.
14. Bleier AR, Jolez FA, Cohen MS, et al. Real-time magnetic resonance imaging of laser heat deposition in tissue. *Magn Reson Med* 1991; 21:132-137.
15. Harms SE, Flamig DP, Hesley KL, et al. Breast MRI: rotating delivery of excitation off-resonance: clinical experience with pathologic correlation. *Radiology* 1993; 187:493-501.
16. Harms SE, Flamig DP. Staging of breast cancer with magnetic resonance. *MRI Clin No Am* 1994; 2:4.
17. Harms SE, Flamig DP. MR Imaging of the Breast *JMRI* 1993; 3:277-283.
18. Harms SE, Flamig DP. In: Special Course Syllabus Breast Imaging Present and future role of MR imaging. *Radiological Society of North America*, 1994:255-261.
19. Harms SE, Jensen RA, Meiches MD, Flamig DP, Evans WP. Silicone-Suppressed 3D MRI of the Breast using Rotating Delivery of Excitation Off-Resonance. *J Comput Assist Tomogr.* 1995; 19:394.
20. Harms SE, Flamig DP, Evans WP, Bown S, Harries SA. MR imaging of the breast: current status and future potential. *AJR.* 1994; 163:1039-1047.
21. Harms SE, Flamig DP, Evans WP, Cheek JH, Peters GN, Savino DA, Jones SE. Magnetic resonance imaging of the breast: present and future roles. *Baylor Proceedings .* 1994; 7(2):21-26.
22. Cross MJ, Harms SE, Cheek JH, Peters GN, Jones RC. New Horizons in the Diagnosis and Treatment of Breast Cancer Using Magnetic Resonance Imaging. *Am J Surg.* 1993; 166:749-755.
23. Pierce WB, Harms SE, Flamig DP, Griffey RH, Evans WP, Hagans JE. Gd-DTPA Enhanced MR imaging of the breast: a new fat suppressed three-dimensional imaging sequence. *Radiology* 1991; 181:757-763.

24. Harms SE, Flamig DP, Hesley KL, Evans WP. Magnetic resonance imaging of the breast. *Magnetic Resonance Quarterly* 1992;8(3):139-155.
25. Harms SE, Flamig DP, Hesley KL, et al. Fat suppressed three-dimensional MR imaging of the breast. *Radiographics* 1993; 13:247-267.
26. Soderstrom CE, Harms SE, Farrell RS, Pruneda JM, Evans WP, Copit DS, Krakos PA, Flamig DP. MRI assessment of residual breast cancer post-lumpectomy. *AJR* (in press).
27. Soderstrom CE, Harms SE, Copit DS, Evans WP, Krakos PA, Farrell RS, Flamig DP. 3D RODEO breast MRI of lesions containing ductal carcinoma in situ. *Radiology* (in press).
28. Miller RW, Harms SE, Alvarez A. Mucinous carcinoma of the breast: potential false negative. *AJR* (In Press)
29. Rodenko GN, Harms SE, Farrell RS, Pruneda JM, Evans WP, Copit DS, Krakos PA, Flamig DP. MR imaging in the management before surgery of lobular carcinoma of the breast: comparison with pathology. *AJR* (In Press)
30. Parker SH, Lovin JD, Jobe WE, Burke BJ, Hopper KD, Yakes WF. Nonpalpable breast lesions: stereotactic automated large-core biopsies. *Radiology* 1991; 403-407.
31. Parker SH; Jobe WE; Dennis MA; Stavros AT; Johnson KK, Yakes WF. US-guided automated large-core breast biopsy. *Radiology* 1993; 187:507-511.
32. Jackman RJ, Nowels KW, Shepard MJ, Finkelstein SI, Marzoni FA. Stereotaxic large-core needle biopsy of 450 nonpalpable breast lesions with surgical correlation I lesions with cancer or atypical hyperplasia. *Radiology* 1994; 193:91-95.
33. Heywang-Koebrunner SH, Halle MD, Requardt H, Oellinger HJ, Fischer U, Viehweg P, Speilmann RP. Optimal procedure and coil design for MR imaging-guided transcutaneous needle localization and biopsy. *Radiology* 1994; 193(P):267.
34. Fischer U, Vosshenrich R, Bruhn H, Funke M, Oestmann JW, Grabbe EH. Breast biopsy guided with MR imaging: experience with two stereotaxic systems. *Radiology* 1994; 193(P):267.
35. Fischer U, Vosshenrich R, Keating D, Bruhn H, Doler W, Oestmann JW, Grabbe E. MR-guided biopsy of suspect breast lesions with a simple stereotaxic add-on-device for surface coils. *Radiology* 1994; 192(1):272-3.
36. Hussman K, Renslo R, Phillips JJ, Fischer HJ, Khalkhali I, Braslau DL, Sinow RM. MR mammographic localization. *Radiology* 1993; 189(3):915-7.
37. Schnall MD, Orel SG, Connick TJ. MR guided biopsy of the breast. *MRI Clin No Am* 1994; 4:585-590.
38. Orel SG, Schnall MD, Newman RW, Powell CM, Torosian MH, Rosato EF. MR imaging-guided localization and biopsy of breast lesions: initial experience. *Radiology* 1994; 193:97-102.
39. Vicini FA, Eberlein TJ, Connolly JL, et al. The optimal extent of resection for patients with stages II or I breast cancer treated with conservative surgery and radiotherapy. *Ann Surg* 1991;214:200-205.
40. Veronesi U, Volterrani F, Luini A, et al. Quadrantectomy versus lumpectomy for small size breast cancer. *Eur J. Cancer* 1990;26:671-673.
41. Ghossein NA, Alpert S, Barba J, et al. Importance of adequate surgical excision prior to radiotherapy in the local control of breast cancer in patients treated conservatively. *Arch Surg* 1992;127:411-415.
42. Kurtz JM, Amalric R, Delouche G, et al. The second ten years: Long term risk of breast conservation in early breast cancer. *Int J Radiat Oncol Biol Phys* 1987;13:1327-1332.
43. Schmidt-Ullrich R, Wazer DE, Tercilla O, et al. Tumor margin assessment as a guide to optimal conservation surgery and irradiation in early stage breast carcinoma. *Int J Radiation Oncology Biol Phys* 1989; 17:733-738.
44. Haga S; Makita M; Shimizu T; Watanabe O; Imamura H; Kajiwarra T; Fujibayashi M. Histopathological study of local residual carcinoma after simulated lumpectomy. *Surg Today* 1995;25:329-33.